Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial-Reference-Cited by-同舟云学术

Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial

Published:2024-07 Issue:7 Volume:24 Page:746-759
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Larivière Ynke^ORCID,Matuvanga Trésor Zola^ORCID,Osang'ir Bernard Isekah^ORCID,Milolo Solange^ORCID,Meta Rachel^ORCID,Kimbulu Primo^ORCID,Robinson Cynthia,Katwere Michael,McLean Chelsea^ORCID,Lemey Gwen^ORCID,Matangila Junior^ORCID,Maketa Vivi^ORCID,Mitashi Patrick^ORCID,Van geertruyden Jean-Pierre^ORCID,Van Damme Pierre^ORCID,Muhindo-Mavoko Hypolite^ORCID

Funder

Coalition for Epidemic Preparedness Innovations

Innovative Medicines Initiative

Publisher

Elsevier BV

Reference24 articles.

1. Health-care worker mortality and the legacy of the Ebola epidemic;Evans;Lancet Glob Health,2015

2. The health impact of the 2014–15 Ebola outbreak;Elston;Public Health,2017

3. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania;Anywaine;J Infect Dis,2019

4. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled phase II clinical trial in Africa;Barry;PLoS Med,2021

5. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial;Ishola;Lancet Infect Dis,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo;Vaccines;2024-07-23

2. Readiness in preventing filovirus epidemics by use of the marketed vaccines against Zaire Ebola virus disease as prototypes;The Lancet Infectious Diseases;2024-07

3. An ancillary care policy in a vaccine trial conducted in a resource-constrained setting: evaluation and policy recommendations;BMJ Global Health;2024-06